DOCSLIB.ORG

Activation of Proteinase-Activated Receptor-2 by Human Kallikrein

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Activation of Proteinase-Activated Receptor-2 by Human Kallikrein View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector ORIGINAL ARTICLE Activation of Proteinase-Activated Receptor-2 by Human Kallikrein-Related Peptidases Kristina Stefansson1, Maria Brattsand1, Dirk Roosterman2, Cordula Kempkes2, Georgeta Bocheva2, Martin Steinhoff2 and Torbjo¨rn Egelrud1 Proteinase-activated receptor-2 (PAR2) is a seven transmembrane spanning, G-protein-coupled receptor, present on the membrane of many cell types including keratinocytes. In skin, PAR2 is suggested to play a regulatory role during inflammation, epidermal barrier function, and pruritus. PAR2 is activated by trypsin-like proteases by a unique mechanism where cleavage of the receptor leads to the release of a small peptide, which activates the receptor as a tethered ligand. The endogenous activators of PAR2 on keratinocytes have not been identified as of yet. Potential candidates are kallikrein-related peptidases (KLKs) expressed by epidermal cells. Therefore, the ability of four human skin-derived KLKs was examined with regard to their capacity to activate PAR2 in vitro.PAR2 cleavage was followed by immunofluorescence analysis and functional activation by measurements of changes in intracellular calcium levels. We found that KLK5 and KLK14, but neither KLK7 nor KLK8, induced PAR2 signalling. We conclude that certain, but not all, epidermal KLKs are capable of activating PAR2. We could also show the coexpression of KLK14 and PAR2 receptor in inflammatory skin disorders. These in vitro results suggest that KLKs may take part in PAR2 activation in the epidermis and thereby in PAR2-mediated inflammatory responses, including epidermal barrier repair and pruritus. The role of KLKs in PAR2 activation in vivo remains to be elucidated. Journal of Investigative Dermatology (2008) 128, 18–25; doi:10.1038/sj.jid.5700965; published online 12 July 2007 INTRODUCTION (Vu et al., 1991; Nystedt et al., 1995; Ishihara et al., 1997; Xu The skin forms a protective barrier not only by means of et al., 1998). These are G-protein-coupled receptors with seven constituting an efficient physico-chemical barrier but also via transmembrane domains, which are activated by a unique its highly active and specialized participation in immune and mechanism dependent on proteolytic cleavage. Upon cleavage inflammatory reactions. The major cellular constituent of the within the N-terminal extracellular part of the receptor, a epidermis, the keratinocyte, has been described as a peptide is released that binds to and irreversibly activates the ‘‘cytokine factory’’ and plays an important role in our immune receptor while still tethered to it. Activation leads to interaction defence (reviewed by Steinhoff et al., 2001). A new concept in with heterotrimeric G-proteins in the plasma membrane and skin immunology is that proteolytic enzymes may act as key downstream signalling events. Proteinases capable of activat- modulators of biological functions in a cytokine-like manner. ing PARs belong to the serine protease family and include Endogenous or exogenous proteinases may influence cells thrombin, trypsin, and cathepsin G. PAR2 is not activated by through the activation of proteinase-activated receptors (PARs) thrombin but has been shown to be activated by the following (reviewed by Steinhoff et al., 2005). proteases in vitro: trypsin, mast cell tryptase, factor Xa, acrosin, Proteinase-activated receptor-2 (PAR2) is a member of the gingipain, and neuronal serine proteases (reviewed by Dery PAR family, which encompasses four PARs, designated PAR1–4 et al., 1998; Macfarlane et al., 2001; Ossovskaya and Bunnett, 2004; Steinhoff et al., 2005). PAR2 is expressed by keratino- 1Department of Public Health and Clinical Medicine, Dermatology and cytes (Santulli et al., 1995; D’Andrea et al., 1998; Steinhoff Venereology, Umea˚ University, Umea˚, Sweden and 2Department of et al., 1999) where it may function as a regulator of growth and Dermatology, University of Mu¨nster, Mu¨nster, Germany differentiation (Derian et al., 1997) and is highly implicated in Correspondence: Dr Maria Brattsand, Department of Public Health and inflammatory reactions (Steinhoff et al., 2005). Recently, PAR2 Clinical Medicine, Dermatology and Venereology, Umea˚ University, Build 6M, 3rd floor, SE-901 85 Umea˚, Sweden. E-mail: was identified as a novel signalling mechanism of the [email protected] epidermal permeability barrier (Hachem et al., 2006). The Abbreviations: KLK, human kallikrein-related peptidase gene; KLK, human endogenous activator of PAR2 in the epidermis, however, has kallikrein-related peptidase protein; KNRK, Kirsten Murine Sarcoma Virus not been identified yet. It has been suggested that mast cell transformed rat kidney epithelial; PAR2, proteinase-activated receptor-2; tryptase may activate PAR during inflammatory conditions PBS, phosphate-buffered saline; rEK, recombinant enterokinase; RT, room 2 temperature upon mast cell infiltration and degranulation (Steinhoff et al., Received 14 March 2007; revised 7 May 2007; accepted 17 May 2007; 1999). Other possibilities include endogenous trypsin-like published online 12 July 2007 proteases present in the epidermis. 18 Journal of Investigative Dermatology (2008), Volume 128 & 2007 The Society for Investigative Dermatology K Stefansson et al. PAR2 Activation by Human KLKs We have previously purified, cloned, and characterized three epidermal serine proteases; human kallikrein-related EK -KLK7 peptidase (KLK) 5 (hK5, stratum corneum tryptic enzyme, EK kDa pro SCTE), KLK7 (hK7, stratum corneum chymotryptic enzyme, KLK7 pro-KLK8 KLK8 204 SCCE), and KLK14 (hK14) (Hansson et al., 1994; Brattsand 116 and Egelrud, 1999; Brattsand et al., 2005; Stefansson et al., 92 2006). KLK8 is another human KLK, which is abundantly 50 present in the stratum corneum (Komatsu et al., 2005a). These four enzymes all belong to the human kallikrein gene 37 family of 15 related serine proteases (Clements et al., 2001; 29 Yousef and Diamandis, 2001) and have different substrate specificities. KLK5 and KLK8 have trypsin-like activity 20 (Brattsand et al., 2005; Rajapakse et al., 2005), whereas KLK7 has chymotrypsin-like activity (Skytt et al., 1995). 6 KLK14 has mainly trypsin-like but also a significant chymo- trypsin-like activity (Brattsand et al., 2005; Felber et al., Figure 1. Preparations of recombinant human tissue KLK protein precursors 2005). These enzymes are here denoted as human kallikrein- and active enzymes. Coomassie brilliant blue stained SDS-PAGE. related peptidases according to the new nomenclature proposed by Lundwall et al. (2006). Given the presence of both PAR2 and KLKs in the account the proportion of active enzyme in the other epidermis, it is plausible that one or several KLKs may preparations, and the fact that electrophoretic analyses function as activators of PAR2 and thus play a role in showed no or negligible degradation of KLK8 (Figure 1), an inflammatory skin diseases. In this work, we investigated assumption was made that at least 30% of the KLK8 whether KLKs 5, 7, 8, or 14 may be capable of activating preparation should be functional. The active KLK8 prepara- PAR2 in vitro. We selected KLKs 5, 7, and 14 because these tion also showed high activity toward chromogenic peptide enzymes are known to be present in the skin in catalytically substrates (see below). active form (Egelrud, 1993; Brattsand and Egelrud, 1999; Stefansson et al., 2006). KLK8 may, besides KLK11, be the Effects of KLKs 5, 7, 8, and 14 on Ca2 þ mobilization most abundant trypsin-like KLK in normal human skin Trypsin, KLK5EK, and KLK14 stimulated Ca2 þ mobilization in (Komatsu et al., 2005a). We show that KLK5 and KLK14, Kirsten Murine Sarcoma Virus transformed rat kidney but neither KLK7 nor KLK8, could activate PAR2. We also epithelial (KNRK)-PAR2 cells (Figure 2a, b, and e), interpreted EK show the colocalization of KLK14 and PAR2 in the epidermis as PAR2 signalling. No reaction was obtained when KLK7 of inflammatory skin disorders. Thus, certain but not all KLKs or KLK8, in concentrations from 0.1 nM up to 10 mM, was used expressed by keratinocytes are potential endogenous activa- (Figure 2c and d). However, subsequent addition of 100 nM tors of PAR2 within the epidermis, and may play a role in trypsin to the same cells gave an expected reaction, epidermal barrier physiology/pathophysiology and itching. confirming the integrity of cells (Figure 2c and d). Addition of rEK in concentrations similar or higher to that present in RESULTS preparations of KLK5EK, KLK7EK, and KLK8 did not lead to any Production and activation of recombinant KLKs detectable Ca2 þ mobilization (data not shown). Figure 3a Production of active KLK5 and KLK14 has been published shows dose response curves. Both trypsin and KLK14 were far EK elsewhere (Brattsand et al., 2005). Purified recombinant more potent activators of PAR2 than KLK5 . The lowest EK pro -KLK7 could, as expected, be activated by recombinant detectable signal was obtained at 50 nM concentration for EK enterokinase (rEK). Recombinant pro-KLK8, having the native KLK14. KLK5 gave a detectable signal at 0.1 mM. Even at propeptide sequence, was also easily activated by rEK. 1 mM, the signal obtained with KLK5 was lower than that for Activation was verified by a mobility shift on SDS-PAGE KLK14 at 50 nM. Neither KLK7 nor KLK8 could activate PAR2. (Figure 1) and by measuring activity toward chromogenic The ability of KLK5 and KLK14 to induce Ca2 þ mobilization peptide substrates. Active KLK8 fusion protein had an in cells via the PAR2 signal system was confirmed using apparent molecular mass of 38.6 kDa according to SDS- human dermal microvascular endothelial cells naturally PAGE analysis (Figure 1). Active-site titration of enzyme expressing functional PAR2 receptors (Figure 3b; Shpacovitch preparations showed that around 30% (KLK7EK) and 60% et al., 2002). (KLK5EK) of the respective enzyme was active when compared with expected activity according to protein Immunofluorescence analyses concentration determined with the DC Protein Assay. Close By using antibodies to the Flag and the HA11 epitopes of the to 100% of the KLK14 preparation was in active form.
Load more

Recommended publications
  • Newly Developed Serine Protease Inhibitors Decrease Visceral Hypersensitivity in a Post-Inflammatory Rat Model for Irritable Bowel Syndrome
    This item is the archived peer-reviewed author-version of: Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome Reference: Ceuleers Hannah, Hanning Nikita, Heirbaut Leen, Van Remoortel Samuel, Joossens Jurgen, van der Veken Pieter, Francque Sven, De Bruyn Michelle, Lambeir Anne-Marie, de Man Joris, ....- New ly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bow el syndrome British journal of pharmacology - ISSN 0007-1188 - 175:17(2018), p. 3516-3533 Full text (Publisher's DOI): https://doi.org/10.1111/BPH.14396 To cite this reference: https://hdl.handle.net/10067/1530780151162165141 Institutional repository IRUA NEWLY DEVELOPED SERINE PROTEASE INHIBITORS DECREASE VISCERAL HYPERSENSITIVITY IN A POST-INFLAMMATORY RAT MODEL FOR IRRITABLE BOWEL SYNDROME. Running title: Serine proteases in visceral hypersensitivity Hannah Ceuleers, Nikita Hanning, Jelena Heirbaut, Samuel Van Remoortel, Michelle De bruyn, Jurgen Joossens, Pieter van der Veken, Anne-Marie Lambeir, Sven M Francque, Joris G De Man, Jean-Pierre Timmermans, Koen Augustyns, Ingrid De Meester, Benedicte Y De Winter Hannah Ceuleers, Nikita Hanning, Jelena Heirbaut, Sven Francque, Joris G De Man, Benedicte Y De Winter, Laboratory of Experimental Medicine and Pediatrics, Division of Gastroenterology, University of Antwerp, Antwerp, Belgium. Samuel Van Remoortel, Jean-Pierre Timmermans, Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium. Jurgen Joossens, Pieter van der Veken, Koen Augustyns, Laboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium. Sven Francque, Antwerp University Hospital, Antwerp, Belgium. Michelle De bruyn, Anne-Marie Lambeir, Ingrid De Meester, Laboratory of Medical Biochemistry, University of Antwerp, Antwerp, Belgium.
    [Show full text]
  • 1 No. Affymetrix ID Gene Symbol Genedescription Gotermsbp Q Value 1. 209351 at KRT14 Keratin 14 Structural Constituent of Cyto
    1 Affymetrix Gene Q No. GeneDescription GOTermsBP ID Symbol value structural constituent of cytoskeleton, intermediate 1. 209351_at KRT14 keratin 14 filament, epidermis development <0.01 biological process unknown, S100 calcium binding calcium ion binding, cellular 2. 204268_at S100A2 protein A2 component unknown <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 3. 33323_r_at SFN stratifin/14-3-3σ binding <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 4. 33322_i_at SFN stratifin/14-3-3σ binding <0.01 structural constituent of cytoskeleton, intermediate 5. 201820_at KRT5 keratin 5 filament, epidermis development <0.01 structural constituent of cytoskeleton, intermediate 6. 209125_at KRT6A keratin 6A filament, ectoderm development <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 7. 209260_at SFN stratifin/14-3-3σ binding <0.01 structural constituent of cytoskeleton, intermediate 8. 213680_at KRT6B keratin 6B filament, ectoderm development <0.01 receptor activity, cytosol, integral to plasma membrane, cell surface receptor linked signal transduction, sensory perception, tumor-associated calcium visual perception, cell 9. 202286_s_at TACSTD2 signal transducer 2 proliferation, membrane <0.01 structural constituent of cytoskeleton, cytoskeleton, intermediate filament, cell-cell adherens junction, epidermis 10. 200606_at DSP desmoplakin development <0.01 lectin, galactoside- sugar binding, extracellular binding, soluble, 7 space, nucleus, apoptosis, 11. 206400_at LGALS7 (galectin 7) heterophilic cell adhesion <0.01 2 S100 calcium binding calcium ion binding, epidermis 12. 205916_at S100A7 protein A7 (psoriasin 1) development <0.01 S100 calcium binding protein A8 (calgranulin calcium ion binding, extracellular 13.
    [Show full text]
  • Biochemical Characterization of Human Kallikrein 8 and Its Possible Involvement in the Degradation of Extracellular Matrix Proteins
    Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular Title matrix proteins Author(s) Rajapakse, Sanath; Ogiwara, Katsueki; Takano, Naoharu; Moriyama, Akihiko; Takahashi, Takayuki Febs Letters, 579(30), 6879-6884 Citation https://doi.org/10.1016/j.febslet.2005.11.039 Issue Date 2005-12-01 Doc URL http://hdl.handle.net/2115/985 Type article (author version) File Information FL579-30.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins Sanath Rajapaksea, Katsueki Ogiwaraa, Naoharu Takanoa, Akihiko Moriyamab, Takayuki Takahashia,* aDivision of Biological Sciences, Graduate School of Science, Hokkaido University, Sapporo, 060-0810 Japan bDivision of Biomolecular Science, Institute of Natural Sciences, Nagoya City University, Nagoya 467-8501, Japan *Correspondence: Takayuki Takahashi, Division of Biological Sciences, Graduate School of Science, Hokkaido University, Sapporo 060-0810, Japan Tel: 81-11-706-2748 Fax: 81-11-706-4851 E-mail: [email protected] 1 Abstract Human kallikrein 8 (KLK8) is a member of the human kallikrein gene family of serine proteases, and its protein, hK8, has recently been suggested to serve as a new ovarian cancer marker. To gain insights into the physiological role of hK8, the active recombinant enzyme was obtained in a pure state for biochemical and enzymatic characterizations. hK8 had trypsin-like activity with a strong preference for Arg over Lys in the P1 position, and its activity was inhibited by typical serine protease inhibitors. The protease degraded casein, fibronectin, gelatin, collagen type IV, fibrinogen, and high-molecular-weight kininogen.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Prostatic Trypsin-Like Kallikrein-Related Peptidases
    Article in press - uncorrected proof Biol. Chem., Vol. 389, pp. 653–668, June 2008 • Copyright ᮊ by Walter de Gruyter • Berlin • New York. DOI 10.1515/BC.2008.078 Review Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs) Andrew J. Ramsay1, Janet C. Reid1, Mark N. cesses by selective cleavage of specific substrates to Adams1, Hemamali Samaratunga2, Ying Dong1, influence cell behaviour (Turk, 2006). Well known physio- Judith A. Clements1 and John D. Hooper1,* logical examples include the proteinases of the blood coagulation (e.g., thrombin) (Davie et al., 1991), digestive 1 Institute of Health and Biomedical Innovation, (e.g., trypsin) (Yamashina, 1956) and wound healing (e.g., Queensland University of Technology, 6 Musk Avenue, plasmin) (Castellino and Ploplis, 2005) cascades. It is Kelvin Grove, Queensland 4059, Australia also clear that dysregulated serine proteinase activity 2 Department of Anatomical Pathology, Sullivan facilitates progression of various diseases including can- Nicolaides Pathology, Taringa 4068, Australia cer (Dano et al., 2005; Turk, 2006; Szabo and Bugge, * Corresponding author 2008). The cleavage site specificity of these enzymes is e-mail: [email protected] indicated by the residue six amino acids before the cat- alytic serine. In the active conformation of the proteinase, this residue is located at the bottom of a pocket in which Abstract the side-chain of the scissile bond of the substrate is inserted. An aspartate or, rarely, a glutamate at this site The prostate is a site of high expression of serine pro- indicates that the serine proteinase will preferentially teinases including members of the kallikrein-related cleave after substrate arginine or lysine residues (trypsin- peptidase (KLK) family, as well as other secreted and like or tryptic substrate specificity); a small hydrophobic membrane-anchored serine proteinases.
    [Show full text]
  • Towards On-Demand E. Coli-Based Cell-Free Protein Synthesis of Tissue Plasminogen Activator
    Benchmark Towards On-Demand E. coli-Based Cell-Free Protein Synthesis of Tissue Plasminogen Activator Seung-Ook Yang 1, Gregory H. Nielsen 1, Kristen M. Wilding 1, Merideth A. Cooper 2, David W. Wood 2 and Bradley C. Bundy 1,* 1 Department of Chemical Engineering, Brigham Young University, Provo, UT 84602, USA; [email protected] (S.-O.Y.); [email protected] (G.H.N.); [email protected] (K.M.W.) 2 Department of Chemical and Biomolecular Engineering, Ohio State University, Columbus, OH 43210, USA; [email protected] (M.A.C.); [email protected] (D.W.W.) * Correspondence: [email protected] Received: 2 March 2019; Accepted: 18 April 2019; Published: 21 June 2019 Abstract: Stroke is the leading cause of death with over 5 million deaths worldwide each year. About 80% of strokes are ischemic strokes caused by blood clots. Tissue plasminogen activator (tPa) is the only FDA-approved drug to treat ischemic stroke with a wholesale price over $6000. tPa is now off patent although no biosimilar has been developed. The production of tPa is complicated by the 17 disulfide bonds that exist in correctly folded tPA. Here, we present an Escherichia coli-based cell-free protein synthesis platform for tPa expression and report conditions which resulted in the production of active tPa. While the activity is below that of commercially available tPa, this work demonstrates the potential of cell-free expression systems toward the production of future biosimilars. The E. coli-based cell-free system is increasingly becoming an attractive platform for low-cost biosimilar production due to recent developments which enable production from shelf-stable lyophilized reagents, the removal of endotoxins from the reagents to prevent the risk of endotoxic shock, and rapid on-demand production in hours.
    [Show full text]
  • Mutant Recombinant Serpins As Highly Specific Inhibitors of Human
    Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14 Loyse M. Felber1,2, Christoph Ku¨ ndig1,2, Carla A. Borgon˜ o3, Jair R. Chagas4, Andrea Tasinato1, Patrice Jichlinski1, Christian M. Gygi1, Hans-Ju¨ rg Leisinger1, Eleftherios P. Diamandis3, David Deperthes1,2 and Sylvain M. Cloutier1,2 1 Urology Research Unit, Department of Urology, CHUV, Epalinges, Switzerland 2 Medical Discovery SA, Epalinges, Switzerland 3 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada 4 Centro Interdisciplinar de Investigacao Bioquimica, Universidade de Mogi das Cruzes, Brazil Keywords The reactive center loop (RCL) of serpins plays an essential role in the inhibitor; kallikrein; protease; serpin inhibition mechanism acting as a substrate for their target proteases. Chan- ges within the RCL sequence modulate the specificity and reactivity of the Correspondence serpin molecule. Recently, we reported the construction of a1-antichymo- D. Deperthes, Urology Research Unit ⁄ Medical Discovery SA, Biopoˆ le, trypsin (ACT) variants with high specificity towards human kallikrein 2 Ch. Croisettes 22, CH-1066 Epalinges, (hK2) [Cloutier SM, Ku¨ ndig C, Felber LM, Fattah OM, Chagas JR, Gygi Switzerland CM, Jichlinski P, Leisinger HJ & Deperthes D (2004) Eur J Biochem 271, Fax: +41 21 6547133 607–613] by changing amino acids surrounding the scissile bond of the Tel: +41 21 6547130 RCL and obtained specific inhibitors towards hK2. Based on this E-mail: [email protected] approach, we developed highly specific recombinant inhibitors of human kallikrein 14 (hK14), a protease correlated with increased aggressiveness of (Received 15 September 2005, revised 1 March 2006, accepted 3 April 2006) prostate and breast cancers.
    [Show full text]
  • Tryptase and Histamine in Patients with Angioedema Due to C1
    106 Alergia Astma Immunologia 2015, 20 (2): 106-110 Tryptase and histamine in patients with angioedema due to C1-inhibitor deficiency (Hereditary Angioedema, HAE) and in patients with mastocytosis Tryptaza i histamina u chorych z napadowym obrzękiem naczynioruchowym w przebiegu niedoboru C1 inhibitora i u chorych z mastocytozą AleksAnder ObtułOwicz 1, MAgdAlenA PirOwskA 1, wOjciech dygA 2, ewA czArnObilskA 2, AnnA wOjAs-Pelc 1 1 The Jagiellonian University, Medical College, Department of Dermatology 2 The Jagiellonian University, Medical College, Department of Clinical and Environmental Allergology Summary Streszczenie Introduction. Tryptase and histamine levels may serve as an indicator of Wprowadzenie. Poziom tryptazy i histaminy w surowicy może być mast cells stimulation related to various diseases, such as mastocytosis, wskaźnikiem pobudzenia komórek tucznych w przebiegu wielu chorób IgE-related allergy, confirming their participation in the pathogenesis. takich jak mastocytoza, alergia IgE zależna, obrzęki napadowe, potwier- Aim. Analyse tryptase and histamine levels and assess the correlation be- dzając ich udział w patomechanizmie tych schorzeń. tween tryptase and histamine levels in serum of the different groups of Cel pracy. Analiza poziomu tryptazy i histaminy w surowicy oraz ocena study patients. zależności pomiędzy ich poziomem w surowicy badanych grup chorych. Material and methods. The determinations were performed in 14 mas- Materiał i metody. Badania wykonano u 14 chorych z mastocytozą, tocytotic patients, including 6 patients with the systemic mastocytosis w tym u 6 chorych z mastocytozą układową i u 8 z pokrzywką barwną, and 8 with urticaria pigmentosa, in 14 with innate angio-motor oedema u 14 chorych z wrodzonym obrzękiem naczynioruchowym w przebiegu due to C1 inhibitor deficiency, and in 10 healthy controls.
    [Show full text]
  • Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer Carla A
    Imaging, Diagnosis, Prognosis Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer Carla A. Borgon‹ o,1, 2 Ta d a a k i K i s h i , 1, 2 Andreas Scorilas,3 Nadia Harbeck,4 Julia Dorn,4 Barbara Schmalfeldt,4 Manfred Schmitt,4 and Eleftherios P. Diamandis1, 2 Abstract Human kallikrein 8 (hK8/neuropsin/ovasin; encoded by KLK8) is a steroid hormone ^ regulated secreted serine protease differentially expressed in ovarian carcinoma. KLK8 mRNA levels are associated with a favorable patient prognosis and hK8 protein levels are elevated in the sera of 62% ovarian cancer patients, suggesting that KLK8/hK8 is a prospective biomarker. Given the above, the aim of the present study was to determine if tissue hK8 bears any prognostic signif- icance in ovarian cancer. Using a newly developed ELISA, hK8 was quantified in 136 ovarian tumor extracts and correlated with clinicopathologic variables and outcome [progression-free survival (PFS); overall survival (OS)] over a median follow-up period of 42 months. hK8 levels in ovarian tumor cytosols ranged from 0 to 478 ng/mg total protein, with a median of 30 ng/mg. An optimal cutoff value of 25.8 ng/mg total protein (74th percentile) was selected based on the ability of hK8 values to predict the PFS of the study population and to categorize tumors as hK8 positive or negative.Women with hK8-positive tumors most often had lower-grade tumors (G1), no residual tumor after surgery, and optimal debulking success (P < 0.05). Univariate and multi- variate analyses revealed that patients with hK8-positive tumors had a significantly longer PFS and OS than hK8-negative patients (P < 0.05).
    [Show full text]
  • Activation Profiles and Regulatory Cascades of the Human Kallikrein-Related Peptidases Hyesook Yoon
    Florida State University Libraries Electronic Theses, Treatises and Dissertations The Graduate School 2008 Activation Profiles and Regulatory Cascades of the Human Kallikrein-Related Peptidases Hyesook Yoon Follow this and additional works at the FSU Digital Library. For more information, please contact [email protected] FLORIDA STATE UNIVERSITY COLLEGE OF ARTS AND SCIENCES ACTIVATION PROFILES AND REGULATORY CASCADES OF THE HUMAN KALLIKREIN-RELATED PEPTIDASES By HYESOOK YOON A Dissertation submitted to the Department of Chemistry and Biochemistry in partial fulfillment of the requirements for the degree of Doctor of Philosophy Degree Awarded: Fall Semester, 2008 The members of the Committee approve the dissertation of Hyesook Yoon defended on July 10th, 2008. ________________________ Michael Blaber Professor Directing Dissertation ________________________ Hengli Tang Outside Committee Member ________________________ Brian Miller Committee Member ________________________ Oliver Steinbock Committee Member Approved: ____________________________________________________________ Joseph B. Schlenoff, Chair, Department of Chemistry and Biochemistry The Office of Graduate Studies has verified and approved the above named committee members. ii ACKNOWLEDGMENTS I would like to dedicate this dissertation to my parents for all your support, and my sister and brother. I would also like to give great thank my advisor, Dr. Blaber for his patience, guidance. Without him, I could never make this achievement. I would like to thank to all the members in Blaber lab. They are just like family to me and I deeply appreciate their kindness, consideration and supports. I specially like to thank to Mrs. Sachiko Blaber for her endless guidance and encouragement. I would like to thank Dr Jihun Lee, Margaret Seavy, Rani and Doris Terry for helpful discussions and supports.
    [Show full text]
  • Somamer Reagents Generated to Human Proteins Number Somamer Seqid Analyte Name Uniprot ID 1 5227-60
    SOMAmer Reagents Generated to Human Proteins The exact content of any pre-specified menu offered by SomaLogic may be altered on an ongoing basis, including the addition of SOMAmer reagents as they are created, and the removal of others if deemed necessary, as we continue to improve the performance of the SOMAscan assay. However, the client will know the exact content at the time of study contracting. SomaLogic reserves the right to alter the menu at any time in its sole discretion. Number SOMAmer SeqID Analyte Name UniProt ID 1 5227-60 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Q15118 2 14156-33 14-3-3 protein beta/alpha P31946 3 14157-21 14-3-3 protein epsilon P62258 P31946, P62258, P61981, Q04917, 4 4179-57 14-3-3 protein family P27348, P63104, P31947 5 4829-43 14-3-3 protein sigma P31947 6 7625-27 14-3-3 protein theta P27348 7 5858-6 14-3-3 protein zeta/delta P63104 8 4995-16 15-hydroxyprostaglandin dehydrogenase [NAD(+)] P15428 9 4563-61 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 P19174 10 10361-25 2'-5'-oligoadenylate synthase 1 P00973 11 3898-5 26S proteasome non-ATPase regulatory subunit 7 P51665 12 5230-99 3-hydroxy-3-methylglutaryl-coenzyme A reductase P04035 13 4217-49 3-hydroxyacyl-CoA dehydrogenase type-2 Q99714 14 5861-78 3-hydroxyanthranilate 3,4-dioxygenase P46952 15 4693-72 3-hydroxyisobutyrate dehydrogenase, mitochondrial P31937 16 4460-8 3-phosphoinositide-dependent protein kinase 1 O15530 17 5026-66 40S ribosomal protein S3 P23396 18 5484-63 40S ribosomal protein
    [Show full text]
  • Type II) Form of Kallikrein 8, a Gene Involved in Learning and Memory
    Cell Research (2009) 19:259-267. npg © 2009 IBCB, SIBS, CAS All rights reserved 1001-0602/09 $ 30.00 ORIGINAL ARTICLE www.nature.com/cr Functional characterization of the human-specific (type II) form of kallikrein 8, a gene involved in learning and memory Zhi-xiang Lu1, 2, 4, Qin Huang3, 4, Bing Su1, 2 1State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China; 2Kunming Primate Research Center, Chinese Academy of Sciences, Kunming 650223, China; 3Institute of Bio- chemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China; 4Graduate School of Chinese Academy of Sciences, Beijing 100049, China Kallikrein 8 (KLK8) is a serine protease functioning in the central nervous system, and essential in many aspects of neuronal activities. Sequence comparison and gene expression analysis among diverse primate species identified a human-specific splice form of KLK8 (type II) with preferential expression in the human brain, which may contribute to the origin of human cognition. To gain insights into the physiological and biochemical role of this novel form, we conducted functional analyses of human type II KLK8. Our results show that type II KLK8 is abundantly expressed in human embryonic stem cells and in embryo brain samples, suggesting a potential role in embryogenesis. There are dramatic expression variations in different individuals and brain regions, which is a reflection of its dynamic role in neural activities. Furthermore, the transcription start site (TSS) of KLK8 is tissue-specific, with a brain-specific TSS found in humans indicating functional specialization.
    [Show full text]